Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

@article{Hoshijima2011DeltasarcoglycanGT,
  title={Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.},
  author={Masahiko Hoshijima and Takeharu Hayashi and Young eun Jeon and Zhenxing Fu and Yusu Gu and Nancy D. Dalton and Mark H. Ellisman and Xiao Nian Xiao and Frank L. Powell and John Jeffrey Ross},
  journal={Circulation. Heart failure},
  year={2011},
  volume={4 1},
  pages={
          89-97
        }
}
BACKGROUND The BIO14.6 hamster provides a useful model of hereditary cardiomyopathies and muscular dystrophy. Previous δ-sarcoglycan (δSG) gene therapy (GT) studies were limited to neonatal and young adult animals and prevented the development of cardiac and skeletal muscle dysfunction. GT of a pseudophosphorylated mutant of phospholamban (S16EPLN) moderately alleviated the progression of cardiomyopathy. METHODS AND RESULTS We treated 4-month-old BIO14.6 hamsters with established cardiac and… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2009